MétaCan
Menu
Back to cohort

Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTR

2025· article· en· W4410801539 on OpenAlexfundno aff
Kitsada Wudhikarn, Megan M. Herr, Min Chen, Michael J. Martens, John H. Baird, Lohith Gowda, Hemalatha G. Rangarajan, Muhammad Bilal Abid, Mohamed A. Kharfan‐Dabaja, Kirsten M. Williams, Siddhartha Ganguly, Jo‐Anne H. Young, Akshay Sharma, Giancarlo Fatobene, Tania Jain, Christopher G. Kanakry, Dipenkumar Modi, Natalie S. Grover, Baheyeldin Salem, Marjorie Vieira Batista, Paschalis Vergidis, Dwight E. Yin, Amer Beitinjaneh, Amar H. Kelkar, Taiga Nishihori, Jennifer Holter‐Chakrabarty, Usama Gergis, Melody Smith, Zeinab El Boghdadly, Christopher E. Dandoy, Hemant S. Murthy, Anna R. Huppler, Miguel‐Angel Perales, Roy F. Chemaly, Laurel A. Thur, Marcie Riches, Jeffery J. Auletta

Bibliographic record

VenueBlood Advances · 2025
Typearticle
Languageen
FieldMedicine
TopicCAR-T cell therapy research
Canadian institutionsnot available
FundersJanssen PharmaceuticalsNational Institute of Environmental Health SciencesNational Institute of Allergy and Infectious DiseasesNational Cancer InstituteOffice of Naval ResearchNational Heart, Lung, and Blood InstituteAlexion Pharmaceuticalsbluebird bioPharmacyclicsAdaptive BiotechnologiesHealth Resources and Services AdministrationKite PharmaDaiichi Sankyo EuropeTakeda OncologyAstraZenecaFundação de Amparo à Pesquisa do Estado de São PauloGenentechMorphoSysU.S. NavyLegend BiotechSangamo TherapeuticsSeagenCTI BiopharmaCareDxBeiGeneSwedish Orphan BiovitrumAstellas PharmaU.S. Department of Health and Human ServicesGlaxoSmithKlineKiadis PharmaMedacJazz PharmaceuticalsNational Institutes of HealthRegeneron PharmaceuticalsHistoGeneticsChildren's Hospital of PhiladelphiaGateway for Cancer ResearchCelgeneOmeros CorporationVertex PharmaceuticalsU.S. Department of DefenseSanofiConselho Nacional de Desenvolvimento Científico e TecnológicoBristol-Myers SquibbCidara TherapeuticsMallinckrodt PharmaceuticalsAstellas Pharma USNovartis Pharmaceuticals CorporationIncytePfizerAmgenAtara BiotherapeuticsActinium PharmaceuticalsGilead Sciences
KeywordsMedicineCytokine release syndromeChimeric antigen receptorLymphomaInternal medicineCumulative incidenceIncidence (geometry)CD19ImmunologyGastroenterologyTransplantationAntigenImmunotherapyCancer

Abstract

fetched live from OpenAlex

ABSTRACT: Infection is increasingly recognized as a significant cause of morbidity and mortality in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) receiving CD19 chimeric antigen receptor (CAR) T-cell therapy. The current study analyzed the natural history, risk factors, and outcomes of infection in 3350 patients with R/R LBCL receiving commercial CD19 CAR T-cell therapy (n = 2804 axicabtagene ciloleucel [axi-cel], n = 546 tisagenlecleucel) from December 2017 to June 2022. Infection developed in 834 patients (24.9%) within 100 days after infusion, resulting in an infection density of 0.43 per 100 patient days and a 100-day cumulative incidence of 22%. Bacterial, viral, and fungal infections were recorded in 527 (15.7%), 374 (11.2%), and 108 patients (3.2%), respectively, with corresponding infection densities of 0.23, 0.15, and 0.04 per 100 patient days. After a 24-month median follow-up, 1482 patients (44%) had died, with infection as the primary cause in 173 cases (12%). The 100-day infection-related mortality (IRM) was 1.6% (95% confidence interval, 1.2-2.0). Patients with a Karnofsky performance score of ≤80, infection history before CAR T-cell therapy, axi-cel therapy, severe cytokine release syndrome (grade ≥3), and severe immune effector cell-associated neurotoxicity syndrome (grade ≥3) had increased infection risk. Infections within 100 days were an independent risk factor for inferior overall survival beyond day 100 after CD19 CAR T-cell therapy. In conclusion, study results show a significant incidence of infection and IRM in patients with R/R LBCL treated with CD19 CAR T-cell therapy. Furthermore, results identify patients at a heightened risk of infection, offering insights to guide potential interventions aimed at mitigating infection and improving patient outcomes after CAR T-cell therapy.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.002
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.001
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.001
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.011
GPT teacher head0.313
Teacher spread0.302 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations10
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueBlood AdvancesSame topicCAR-T cell therapy researchFrench-language works237,207